Our results unexpectedly associate SGLT2 inhibitor use with a higher risk of mortality, an effect that was persistent in multiple myeloma and acute myeloid leukemia after controlling for both chronic kidney disease and congestive heart failure. This evidence concerns the gene SLC5A2 and AL amyloidosis.